Publication: Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
Loading...
Identifiers
Date
2018-11-19
Authors
Sanoja-Flores, L
Flores-Montero, J
Garcés, J J
Paiva, B
Puig, N
García-Mateo, A
García-Sánchez, O
Corral-Mateos, A
Burgos, L
Blanco, E
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p
Description
MeSH Terms
Adult
Aged
Aged, 80 and over
Biomarkers
Diagnosis, Differential
Female
Flow Cytometry
Humans
Immunophenotyping
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Neoplasm Staging
Neoplastic Cells, Circulating
Plasma Cells
Prognosis
Sensitivity and Specificity
Aged
Aged, 80 and over
Biomarkers
Diagnosis, Differential
Female
Flow Cytometry
Humans
Immunophenotyping
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Neoplasm Staging
Neoplastic Cells, Circulating
Plasma Cells
Prognosis
Sensitivity and Specificity